• 1
    Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262274.
  • 2
    Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2010 data report. Am J Transplant 2012; 12(Suppl 1): 1156.
  • 3
    Fishman JA. Infections in immunocompromised hosts and organ transplant recipients: Essentials. Liver Transpl 2011; 17(Suppl 3): S34S37.
  • 4
    Fishman JA, Issa NC. Infection in organ transplantation: Risk factors and evolving patterns of infection. Infect Dis Clin North Am 2010; 24: 273283.
  • 5
    Glotzbecker B, Duncan C, Alyea E, 3rd, Campbell B, Soiffer R. Important drug interactions in hematopoietic stem cell transplantation: What every physician should know. Biol Blood Marrow Transplant 2012; 18: 9891006.
  • 6
    Srinivas TR, Meier-Kriesche HU, Kaplan B. Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant 2005; 5: 207217.
  • 7
    Rabie R, Mumtaz K, Renner EL. Efficacy of antiviral therapy for hepatitis C post liver transplant on cyclosporine versus tacrolimus: A systematic review and meta-analysis. Liver Transpl 2013; 19:3648.
  • 8
    Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012; 93: 10751085.
  • 9
    Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 2002; 35: 5361.
  • 10
    Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: Incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 2009; 88: 135141.
  • 11
    Nyman HA, Dowling TC, Hudson JQ, Peter WL, Joy MS, Nolin TD. Comparative evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing: An opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy 2011; 3: 11301144.
  • 12
    Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23: 106131.
  • 13
    Page RL, 2nd, Ruscin JM, Fish D, Lapointe M. Possible interaction between intravenous azithromycin and oral cyclosporine. Pharmacotherapy 2001; 21: 14361443.
  • 14
    Ljutic D, Rumboldt Z. Possible interaction between azithromycin and cyclosporin: A case report. Nephron 1995; 70: 130.
  • 15
    Shullo MA, Schonder K, Teuteberg JJ. Elevated tacrolimus levels associated with intravenous azithromycin and ceftriaxone: A case report. Transplant Proc 2010; 42: 18701872.
  • 16
    Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 14411458.
  • 17
    Thomas PP, Manivannan J, John GT, Jacob CK. Sirolimus and ketoconazole co-prescription in renal transplant recipients. Transplantation 2004; 77: 474475.
  • 18
    Gonzalez F, Espinoza M, Herrera P, et al. Everolimus versus azathioprine in a cyclosporine and ketoconazole-based immunosuppressive therapy in kidney transplant: 3-year follow-up of an open-label, prospective, cohort, comparative clinical trial. Transplant Proc 2010; 42: 270272.
  • 19
    el-Agroudy AE, Sobh MA, Hamdy AF, Ghoneim MA. A prospective, randomized study of coadministration of ketoconazole and cyclosporine a in kidney transplant recipients: Ten-year follow-up. Transplantation 2004; 77: 13711376.
  • 20
    El-Dahshan KF, Bakr MA, Donia AF, Badr Ael S, Sobh MA. Ketoconazole-tacrolimus coadministration in kidney transplant recipients: Two-year results of a prospective randomized study. Am J Nephrol 2006; 26: 293298.
  • 21
    Dodds ES, Drew RH, Perfect JR. Antifungal pharmacodynamics: Review of the literature and clinical applications. Pharmacotherapy 2000; 20: 13351355.
  • 22
    Page RL, 2nd, Mueller SW, Levi ME, Lindenfeld J. Pharmacokinetic drug-drug interactions between calcineurin inhibitors and proliferation signal inhibitors with anti-microbial agents: Implications for therapeutic drug monitoring. J Heart Lung Transplant 2011; 30: 124135.
  • 23
    Pfizer Incorporated. VFEND I.V. (voriconazole for Injection); VFEND Tablets (voriconazole); VFEND (voriconazole for oral suspension), United States prescribing information, New York, NY, 2011.
  • 24
    Surowiec D, DePestel DD, Carver PL. Concurrent administration of sirolimus and voriconazole: A pilot study assessing safety and approaches to appropriate management. Pharmacotherapy 2008; 28: 719729.
  • 25
    Novartis Pharmaceuticals Corporation. Zortress (everolimus) tablets for oral use, United States prescribing information, East Hanover, NJ, 2012.
  • 26
    Billaud EM, Antoine C, Berge M, Abboud I, Lefeuvre S, Benammar M, et al. Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient. Clin Drug Investig 2009; 29: 481486.
  • 27
    Pea F, Baccarani U, Tavio M, Cojutti P, Adani GL, Londero A, et al. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. Ann Pharmacother 2008; 42: 17111716.
  • 28
    Schering Corporation. Noxafil (posaconazole) oral suspension for oral use,United States prescribing information, Kenilworth, NJ, 2011.
  • 29
    Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007; 27: 825834.
  • 30
    Moton A, Ma L, Krishna G, Martinho M, Seiberling M, McLeod J. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin 2009; 25: 701707.
  • 31
    Vasquez E, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: A drug interaction in kidney transplant patients. Clin Transplant 2001; 15: 9599.
  • 32
    Vasquez EM, Shin GP, Sifontis N, Benedetti E. Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. Ther Drug Monit 2005; 27: 587591.
  • 33
    Mieles L, Venkataramanan R, Yokoyama I, Warty VJ, Starzl TE. Interaction between FK506 and clotrimazole in a liver transplant recipient. Transplantation 1991; 52: 10861087.
  • 34
    Choy M. Tacrolimus interaction with clotrimazole: A concise case report and literature review. P T 2010; 35: 568569.
  • 35
    Merck and Company, Inc. Cancidas (caspofungin) injection for intravenous use, United States prescribing information, Whitehouse Station, NJ, 2010.
  • 36
    Marr KA, Hachem R, Papanicolaou G, et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004; 6: 110116.
  • 37
    Groetzner J, Kaczmarek I, Wittwer T, et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant 2008; 27: 16.
  • 38
    Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: A comparison. Drugs 2011; 71: 1141.
  • 39
    Hebert MF, Blough DK, Townsend RW, et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 10181024.
  • 40
    Astellas Pharma US Inc. Mycamine (micafungin) injection for intravenous use, United States prescribing information, Deerfield, IL, 2011.
  • 41
    Hebert MF, Townsend RW, Austin S, et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 954960.
  • 42
    Dowell JA, Stogniew M, Krause D, Henkel T, Weston IE. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005; 45: 227233.
  • 43
    Dowell JA, Stogniew M, Krause D, Henkel T, Damle B. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol 2007; 47: 305314.
  • 44
    Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363: 20042014.
  • 45
    Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 28162820.
  • 46
    Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the hcv protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56: 16221630.
  • 47
    Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55: 16201628.
  • 48
    Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 2027.
  • 49
    Sam T, Tichy E, Emre S., Schilsky M.Pharmacokinetic effects of boceprevir co-administration on cyclosporine exposure in liver transplant recipients. Am J Transplant 2012; 12(Suppl 3): 430 (Abstract 1370).
  • 50
    de Oliveira Pereira A, Shin H, Safdar A, et al. Post liver transplant therapy with telaprevir for recurrent hepatitis C. Am J Transplant 2012; 12 (Suppl 3): 430 (Abstract 1369).
  • 51
    Pungpapong S, Murphy J, Henry T, et al. Iniital experience utilizing telaprevir with peginterferon and ribavirin for treatment of hepatitis C genotype 1 after liver transplantation. Am J Transplant 2012; 12(Suppl 3): 430 (Abstract 1367).
  • 52
    Rogers C, Stevens D, Kim M, Ghaziani T, Malik R, Curry M. Telaprevir can be used safely with concomitant tacrolimus in the post-transplant setting. Am J Transplant 2012; 12(Suppl 3): 431 (Abstract 1372).
  • 53
    Burton JR, Everson GT. Initial experience with telaprevir for treating hepatitis C virus in liver recipients: Virologic response, safety, and tolerability. Am J Transplant 2012; 12(Suppl 3): 188 (Abstract LB 01).
  • 54
    Ha YE, Joo EJ, Park SY, et al. Tacrolimus as a risk factor for tuberculosis and outcome of treatment with rifampicin in solid organ transplant recipients. Transpl Infect Dis. 2012; 14: 626634.
  • 55
    Manitpisitkul W, McCann E, Lee S, Weir MR. Drug interactions in transplant patients: What everyone should know. Curr Opin Nephrol Hypertens 2009; 18: 404411.
  • 56
    Lopez-Montes A, Gallego E, Lopez E, et al. Treatment of tuberculosis with rifabutin in a renal transplant recipient. Am J Kidney Dis 2004; 44: e59e63.
  • 57
    Chenhsu RY, Loong CC, Chou MH, Lin MF, Yang WC. Renal allograft dysfunction associated with rifampin-tacrolimus interaction. Ann Pharmacother 2000; 34: 2731.
  • 58
    Modry DL, Stinson EB, Oyer PE, Jamieson SW, Baldwin JC, Shumway NE. Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation 1985; 39: 313314.
  • 59
    Kovarik JM, Hartmann S, Figueiredo J, Rouilly M, Port A, Rordorf C. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 2002; 36: 981985.
  • 60
    Ngo BT, Pascoe M, Khan D. Drug interaction between rifampicin and sirolimus in transplant patients. Saudi J Kidney Dis Transpl 2011; 22: 112115.
  • 61
    Bhaloo S, Prasad GV. Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: A case report. Transplant Proc 2003; 35: 24492451.
  • 62
    Naesens M, Kuypers DR, Streit F, et al. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients. Clin Pharmacol Ther 2006; 80: 509521.
  • 63
    Genetech Incorporated. Mycophenolate mofetil (CellCept) capsules, tablets and oral suspension and mycophenolate mofetil hydrochloride for injection, United States prescribing information. South San Francisco, CA, 2012.
  • 64
    Novartis Pharmaceuticals Corporation. Mycophenolic acid delayed release tablets as mycophenolate sodium (Myfortic) for oral use, United States prescribing information. East Hanover, NJ, 2010.
  • 65
    Novartis Pharmaceuticals Corporation. Coartem (artemether/lumefantrine) tablets for oral use, United States prescribing information. East Hanover, NJ, 2010.